Antipsychotic Adjuvant Treatment in OCD

2017 ◽  
Vol 41 (S1) ◽  
pp. S642-S642
Author(s):  
L. Monte. Reula ◽  
H. Saiz García ◽  
A. Portilla Fernández

Antidepressant drugs selective inhibitors of serotonin reuptake (IRS) are the drugs effective in obsessive compulsive disorder. It has not been proven more effective none of them except clomipramine. Around 40–60% of the Patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs).Two cases are presented in relation to this disorder and its treatment.Twenty-three year old woman begins to present anhedonia, apathy, isolation and low mood. Treatment was initiated with escitalopram with partial improvement.Obsessive component traitsThirty year old man with obsessive clinic of years of evolution, with worsening in recent months treatment with 200 mg sertraline.In both cases treatment with oral aripiprazole it was associated with a dose of 5 mg daily with improvement in obsessive symptoms.ResultsThe efficacy of aripiprazole as adjunctive drug treatment and obsessive anxiety is observed. However, we must take into account the potential risks posed as neuroleptic malignant syndrome and QTc prolongation.ConclusionAripiprazole is an antipsychotic which has a novel mechanism of action to be a partial agonist of dopamine D2 receptors. This fact has led to its inclusion in the group of antipsychotics called third generation, also called partial dopamine agonists, dopamine stabilizers or “dopamine-serotonin modulators system.” Its most common side effects such as nausea, headaches, agitation and akathisia were observed in studies on schizophrenia, schizoaffective disorder and bipolar disorder. Unlike other atypical antipsychotics, is considered a relatively neutral drug to weight gain, hyperprolactinemia, changes in metabolic parameters and sedation.Disclosure of interestThe authors have not supplied their declaration of competing interest.

2009 ◽  
Vol 3 (1) ◽  
pp. 15-26
Author(s):  
Giuseppe Maina ◽  
Enrico Pessina ◽  
Andrea Aguglia ◽  
Filippo Bogetto

The recommended pharmacological agents for the treatment of Obsessive-Compulsive Disorder (OCD) are serotonin reuptake inhibitors (SRI), used also as antidepressant drugs. Nevertheless, the therapeutic profile of SRIs shows a lot of differences in OCD and in depression, as demonstrated in the trials here described. From a pharmacological point of view, antidepressant effect can be obtained with every monoamine reuptake inhibitor, whereas a predominant serotonin reuptake inhibition is required to result in an antiobsessive effect; moreover, adding pindolol to SSRI therapy, generate opposite effects on SSRI response latency. From a clinical point of view, the trials have highlighted differences in the following fields: response rate, therapeutic dose, response latency, response curve. Taken together, these findings suggest that SRIs have two different clinical properties, antiobsessional effect and antidepressant effect, that could be due to different mechanisms of actions: further studies have to be performed the better to understand the pathophysiology of OCD.


Sign in / Sign up

Export Citation Format

Share Document